213 related articles for article (PubMed ID: 34714120)
41. A double-blind, randomized, placebo/active controlled crossover evaluation of the efficacy and safety of Ritalin ® LA in children with attention-deficit/hyperactivity disorder in a laboratory classroom setting.
Schulz E; Fleischhaker C; Hennighausen K; Heiser P; Oehler KU; Linder M; Haessler F; Huss M; Warnke A; Schmidt M; Schulte-Markworth M; Sieder C; Klatt J; Tracik F
J Child Adolesc Psychopharmacol; 2010 Oct; 20(5):377-85. PubMed ID: 20973708
[TBL] [Abstract][Full Text] [Related]
42. Dose Proportionality and Steady-State Pharmacokinetics of Serdexmethylphenidate/Dexmethylphenidate, a Novel Prodrug Combination to Treat Attention-Deficit/Hyperactivity Disorder.
Braeckman R; Guenther S; Mickle TC; Barrett AC; Smith A; Oh C
J Child Adolesc Psychopharmacol; 2022 Jun; 32(5):288-295. PubMed ID: 35666231
[No Abstract] [Full Text] [Related]
43. Efficacy and Safety of HLD200, Delayed-Release and Extended-Release Methylphenidate, in Children with Attention-Deficit/Hyperactivity Disorder.
Pliszka SR; Wilens TE; Bostrom S; Arnold VK; Marraffino A; Cutler AJ; López FA; DeSousa NJ; Sallee FR; Incledon B; Newcorn JH
J Child Adolesc Psychopharmacol; 2017 Aug; 27(6):474-482. PubMed ID: 29172680
[TBL] [Abstract][Full Text] [Related]
44. Efficacy, Safety, and Tolerability of a Novel Methylphenidate Extended-Release Oral Suspension (MEROS) in ADHD.
Robb AS; Findling RL; Childress AC; Berry SA; Belden HW; Wigal SB
J Atten Disord; 2017 Dec; 21(14):1180-1191. PubMed ID: 24874348
[TBL] [Abstract][Full Text] [Related]
45. A double-blind, placebo-controlled study of modified-release methylphenidate in children with attention-deficit/hyperactivity disorder.
Greenhill LL; Findling RL; Swanson JM;
Pediatrics; 2002 Mar; 109(3):E39. PubMed ID: 11875167
[TBL] [Abstract][Full Text] [Related]
46. A Phase III, Randomized, Double-Blind, Placebo-Controlled Trial Assessing the Efficacy and Safety of Viloxazine Extended-Release Capsules in Adults with Attention-Deficit/Hyperactivity Disorder.
Nasser A; Hull JT; Chaturvedi SA; Liranso T; Odebo O; Kosheleff AR; Fry N; Cutler AJ; Rubin J; Schwabe S; Childress A
CNS Drugs; 2022 Aug; 36(8):897-915. PubMed ID: 35896943
[TBL] [Abstract][Full Text] [Related]
47. Lisdexamfetamine dimesylate and mixed amphetamine salts extended-release in children with ADHD: a double-blind, placebo-controlled, crossover analog classroom study.
Biederman J; Boellner SW; Childress A; Lopez FA; Krishnan S; Zhang Y
Biol Psychiatry; 2007 Nov; 62(9):970-6. PubMed ID: 17631866
[TBL] [Abstract][Full Text] [Related]
48. Efficacy and safety of dexmethylphenidate extended-release capsules in children with attention-deficit/hyperactivity disorder.
Greenhill LL; Muniz R; Ball RR; Levine A; Pestreich L; Jiang H
J Am Acad Child Adolesc Psychiatry; 2006 Jul; 45(7):817-23. PubMed ID: 16832318
[TBL] [Abstract][Full Text] [Related]
49. Efficacy of two long-acting methylphenidate formulations in children with attention- deficit/hyperactivity disorder in a laboratory classroom setting.
Silva R; Muniz R; Pestreich LK; Brams M; Childress A; Lopez FA
J Child Adolesc Psychopharmacol; 2005 Aug; 15(4):637-54. PubMed ID: 16190795
[TBL] [Abstract][Full Text] [Related]
50. A double-blind, placebo-controlled withdrawal trial of dexmethylphenidate hydrochloride in children with attention deficit hyperactivity disorder.
Arnold LE; Lindsay RL; Conners CK; Wigal SB; Levine AJ; Johnson DE; West SA; Sangal RB; Bohan TP; Zeldis JB
J Child Adolesc Psychopharmacol; 2004; 14(4):542-54. PubMed ID: 15662146
[TBL] [Abstract][Full Text] [Related]
51. Efficacy and Safety of a Long-Acting Multilayer-Release Methylphenidate Formulation (PRC-063) in the Treatment of Adolescent Attention-Deficit/Hyperactivity Disorder: A Randomized, Double-Blind Clinical Trial with a 6-Month Open-Label Extension.
Weiss MD; Cutler AJ; Kollins SH; Donnelly GAE
J Child Adolesc Psychopharmacol; 2021 Nov; 31(9):610-622. PubMed ID: 34637343
[No Abstract] [Full Text] [Related]
52. Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Adult Laboratory Classroom Study of the Efficacy and Safety of PRC-063 (Extended-Release Methylphenidate) for the Treatment of ADHD.
Childress A; Cutler AJ; Marraffino AH; Bhaskar S; Donnelly G
J Atten Disord; 2022 Apr; 26(6):857-869. PubMed ID: 34189995
[TBL] [Abstract][Full Text] [Related]
53. Efficacy and safety of immediate-release methylphenidate treatment for preschoolers with ADHD.
Greenhill L; Kollins S; Abikoff H; McCracken J; Riddle M; Swanson J; McGough J; Wigal S; Wigal T; Vitiello B; Skrobala A; Posner K; Ghuman J; Cunningham C; Davies M; Chuang S; Cooper T
J Am Acad Child Adolesc Psychiatry; 2006 Nov; 45(11):1284-1293. PubMed ID: 17023867
[TBL] [Abstract][Full Text] [Related]
54. Efficacy and safety of mixed amphetamine salts extended release (Adderall XR) in the management of attention-deficit/hyperactivity disorder in adolescent patients: a 4-week, randomized, double-blind, placebo-controlled, parallel-group study.
Spencer TJ; Wilens TE; Biederman J; Weisler RH; Read SC; Pratt R
Clin Ther; 2006 Feb; 28(2):266-79. PubMed ID: 16678648
[TBL] [Abstract][Full Text] [Related]
55. A Randomized, Placebo-Controlled Laboratory Classroom Study of the Efficacy and Safety of Dasotraline in Children With ADHD.
Wigal S; Tsai J; Bates JA; Sarma K; Tortorich D; Zhu H; Goldman R
J Atten Disord; 2022 Aug; 26(10):1357-1368. PubMed ID: 35048745
[TBL] [Abstract][Full Text] [Related]
56. Randomized, double-blind, placebo-controlled, crossover study of the efficacy and safety of lisdexamfetamine dimesylate in adults with attention-deficit/hyperactivity disorder: novel findings using a simulated adult workplace environment design.
Wigal T; Brams M; Gasior M; Gao J; Squires L; Giblin J;
Behav Brain Funct; 2010 Jun; 6():34. PubMed ID: 20576091
[TBL] [Abstract][Full Text] [Related]
57. Once-a-day Concerta methylphenidate versus three-times-daily methylphenidate in laboratory and natural settings.
Pelham WE; Gnagy EM; Burrows-Maclean L; Williams A; Fabiano GA; Morrisey SM; Chronis AM; Forehand GL; Nguyen CA; Hoffman MT; Lock TM; Fielbelkorn K; Coles EK; Panahon CJ; Steiner RL; Meichenbaum DL; Onyango AN; Morse GD
Pediatrics; 2001 Jun; 107(6):E105. PubMed ID: 11389303
[TBL] [Abstract][Full Text] [Related]
58. A randomized, double-blind, placebo-controlled, parallel-group study to evaluate the efficacy and safety of osmotic-controlled release oral delivery system methylphenidate HCl in adults with attention-deficit/hyperactivity disorder in Japan.
Takahashi N; Koh T; Tominaga Y; Saito Y; Kashimoto Y; Matsumura T
World J Biol Psychiatry; 2014 Aug; 15(6):488-98. PubMed ID: 24456065
[TBL] [Abstract][Full Text] [Related]
59. Measuring methylphenidate response in attention-deficit/hyperactvity disorder: how are laboratory classroom-based measures related to parent ratings?
Sonuga-Barke EJ; Coghill D; DeBacker M; Swanson J
J Child Adolesc Psychopharmacol; 2009 Dec; 19(6):691-8. PubMed ID: 20035587
[TBL] [Abstract][Full Text] [Related]
60. Methylphenidate hydrochloride modified-release in adults with attention deficit hyperactivity disorder: a randomized double-blind placebo-controlled trial.
Huss M; Ginsberg Y; Tvedten T; Arngrim T; Philipsen A; Carter K; Chen CW; Kumar V
Adv Ther; 2014 Jan; 31(1):44-65. PubMed ID: 24371021
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
